Biogen appears to be subtly signaling it has a larger appetite for M&A than previously stated.
In an exclusive interview with Endpoints News, Biogen head …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Health systems drowning in messages from patients are grasping for new ways to manage the deluge — including charging for especially time-consuming responses. In recent
Pediatric acute-onset neuropsychiatric syndrome (PANS) — along with the related pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) — may be a controversial diagnosis,
Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for at least 15 months in a large phase 3 trial.